Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06016972 · ClinicalTrials.gov registry record · Phase 2
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
A Phase 2 study, sponsored by Qlaris Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT06016972 is a Phase 2 study that has completed, run by Qlaris Bio. The registered enrollment target is 63 participants.
The verdict
NCT06016972, a Phase 2 study, has completed, sponsored by Qlaris Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
Interventions
- DRUG Experimental: QLS-111 ophthalmic solution, (0.015%)
- DRUG Experimental: QLS-111 ophthalmic solution, (0.03%)
- DRUG Experimental: QLS-111 ophthalmic solution, (0.075%)
- OTHER QLS-111 ophthalmic vehicle solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2024-03-05 |
| Est. Completion | 2024-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06016972
The ClinicalTrials.gov registry entry for NCT06016972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qlaris Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Experimental: QLS-111 ophthalmic solution, (0.015%) is the first listed.
NCT06016972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06016972 about?
NCT06016972 is a clinical study titled "Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients". Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.
What is the current status of trial NCT06016972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2024-03-05. Estimated completion is 2024-08-20.
What interventions are being tested in trial NCT06016972?
The interventions under investigation include: Experimental: QLS-111 ophthalmic solution, (0.015%) (DRUG), Experimental: QLS-111 ophthalmic solution, (0.03%) (DRUG), Experimental: QLS-111 ophthalmic solution, (0.075%) (DRUG), QLS-111 ophthalmic vehicle solution (OTHER).
Who is sponsoring clinical trial NCT06016972?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.